Salute e Benessere

Casino Group Communication

Update on new money equity offers Paris, 4 July 2023Casino announces today that it has received the following proposals to strengthen the Group's equity capital: A proposal from EP Global Commerce a.s. and Fimalac, and A proposal from 3F Holding These two proposals will be analyzed and presented to the ad hoc committee of Casino's Board of Directors today, and then to the creditors at a meeting organized on July 5 under the aegis of the conciliators. Casino's governance bodies...

Vistin Pharma ASA: Results of offer to buy back shares

4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the "Company") dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the “Offer”) in connection with its Long Term Incentive Plan (LTIP) for the executive management. The Offer expired Monday 3 July 2023 at 16:00 hours CEST. The Company has resolved to buy back 220 000 shares at a price of NOK 23,00 per share (the “Purchase Price”). The Purchase Price was determined…

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma…

Key Takeaways from the Bispecific Antibody Competitive Landscape Report Key Takeaways from the Bispecific Antibody Competitive Landscape Report Request a sample and discover the recent advances in bispecific antibody treatment @Bispecific Antibody Competitive Landscape Report Bispecific Antibody Overview Bispecific antibodies have been developed, with one antigen-binding site directed against the CD3 receptor (which activates cytotoxic T lymphocytes) and the other directed...

Virbac reassesses its 2023 growth and Adjusted EBIT1 forecasts

Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year. As a reminder, at constant rates and scope, our initial forecast for revenue growth was within a range of between 4% and 6% while our initial forecast for ratio of Adjusted EBIT 1was within a range of between 13% and 14%. We now expect revenue growth at constant rates and scope within a range of between 0% and 4%. The ratio of Adjusted EBIT 1should now...

AAHRPP Awards Accreditation to King Abdullah International Medical Research…

AAHRPP has accredited more than 600 research entities across the U.S. and in Australia, Belgium, Brazil, Canada, China, India, Japan, Jordan, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand. AAHRPP has accredited more than 600 research entities across the U.S. and inAustralia,Belgium,Brazil,Canada,China,India,Japan,Jordan,Mexico, Republic of Korea,Saudi Arabia,Singapore,Taiwan, andThailand. All major U.S. independent...

Machine Learning in Pharmaceutical Industry Market to Exhibit 37.9% CAGR and…

As per the report published by Research Dive, the global machine learning in pharmaceutical industry market is anticipated to generate a revenue of $26,151.8 million and grow at a fascinating CAGR of 37.9% over the analysis timeframe from 2022 to 2031. As pe r the report published by Research Dive, theglobal machine learning in pharmaceutical industry marketis anticipated to generate a revenue of$26,151.8 millionand grow at a fascinating CAGR of 37.9% over the analysis timeframe from...

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF…

Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlementgénéral of the l'AMF) As of June 30, 2023 Total number of shares...

Molecular Diagnostics Market worth $28.6 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833 Browse in-depth TOC on "Molecular Diagnostics Market" 238 - Tables 49 - Figures 319 - Pages Molecular Diagnostics Market Scope: In 2022, the infectious disease diagnostics segment held the largest share of the molecular diagnostics market, by application segment The...

Additional Infant Bacterial Therapeutics product receives FDA orphan drug…

The FDA has granted orphan drug designation for IBT's product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to increased mortality. Hospital stays for these infants are commonly long and costly.Orphan drugs are either drugs or biologics intended for the treatment, diagnosis or prevention of rare diseases or disorders affecting less than 200 000 patients in the USA per year. An orphan drug...

Bone Cement Market Zooms Towards Billion-Dollar Valuation: Estimated to Reach…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=17380 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=17380 Browse in-depth TOCon" Bone Cement Market " 202 - Pages 126 – Tables 37 – Figures Bone Cement Market Driven by Increasing Incidence of Sports Injuries and Growing Geriatric Population The global Bone Cement Market is experiencing robust growth, fueled by several key drivers in the healthcare...

eureKARE seeks disruptive synthetic biology solutions to tackle environmental…

The 2 nd edition of the eurekAWARDS is launched!Luxembourg, Belgium, Monaco, and Paris, France– 3 July 2023: eureKARE, a pioneering company focused on financing and building next generation synthetic-biology based biotechnology companies, is pleased to announce the opening of its science-based pitch competition,eurekAWARDS 2023. The unique contest aims to identify and support novel, disruptive synthetic biology solutions that address pressing global challenges. This...

NorthX Biologics, a leading Nordic development and manufacturing organisation…

The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University Hospital. In addition, 30 staff members who currently operate the facility will also join NorthX. The site and staff have a long history with extensive experience of serving both Valneva internally and also working with external customers on a contract development and manufacturing basis. With expertise in mammalian expression systems and viral...

Prevention and Immunization, the Key to Achieve a More Efficient Healthcare…

Experts in vaccination from Germany, France and Spain, invited by the Bamberg Foundation, met in Berlin to discuss the key strategic priorities that will contribute to the improvement of immunization of adults against vaccine-preventable diseases (VPDs) “Vaccines are for life, not only children,” said Prof. Dr. Beate Kampmann, Director of the Institute for International Health, Scientific Directors, Charité Centre for Global Health (Germany).The 3 points on which they focused, and which...

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 3July 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the...

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

AC ImmuneShowcasingPrecision Medicine Programsat AAIC 2023Lausanne, Switzerland,July3 ,2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC 2023), taking place in Amsterdam, The Netherlands, on July 16-20, 2023.The presentations will include a poster detailing the...

Sanofi and Marken transform the pharma supply chain

Its focus is on therapeutic areas that include diabetes, oncology, immunology and inflammation, rare diseases, and vaccines for diseases including influenza polio and meningitis. Its focus is on therapeutic areas that include diabetes, oncology, immunology and inflammation, rare diseases, and vaccines for diseases including influenza polio and meningitis. The company offers a wide range of prescription drugs, over-the-counter medications, and vaccines to improve health outcomes for patients...

OSF HEALTHCARE EMPOWERS PATIENTS WITH DIGITAL ADVANCEMENTS

LONDON, July 3, 2023 /PRNewswire/ -- OSF HealthCare is an integrated health system that is owned by The Sisters of the Third Order of St Francis. Headquartered in Peoria, Illinoi, it has 15 hospitals – 10 acute care and five critical access, as well as 2,084 licensed beds and 24,000 Mission Partners in over 150 locations. LONDON,July 3, 2023/PRNewswire/ -- OSF HealthCare is an integrated health system that is owned by The Sisters of the Third Order of St Francis. Headquartered in Peoria,...

BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc's rights…

BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider information, July 3 rd2023 at 1:10 pmNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL. The rights issue resolved by BBS-Bioactive Bone Substitutes Plc's (“BBS” or the “Company”) Board of Directors on 5 June 2023 (the “Offering”)...

Zealand Pharma announces positive results from Part 1 of multiple ascending dose…

Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6%, 3.6% and 4.2% weight loss following single doses of 0.7, 1.4 and 2.4 mg ZP8396, already reportedPart 2 investigates once-weekly dosing for 16 weeks and has been initiated, exploring significantly higher doses of...

The CHAIMELEON Open Challenges: a unique opportunity for European scientists to…

The CHAIMELEON Open Challenges offers a unique opportunity for researchers to collaborate and develop new solutions that can have a significant impact on cancer diagnosis and treatment. The registration for the challenges will open on July 3rd, 2023 and will be available until the end of August 2023. The challenges will be divided in two phases: the Classification Phase and the Championship Phase. The CHAIMELEON Open Challenges offers a unique opportunity for researchers to collaborate and...

SHL Medical acquires 100% of the shares in Swiss company LCA Automation

The acquisition of LCA Automation is part of SHL Medical's ongoing strategy to respond to the exponentially growing market demand, expand its global presence, and further strengthen SHL Medical's vertical capabilities globally. SHL Medical and LCA Automation have a strong track record of excellence in automation. The combination of their expertise and long-standing experience in different industries allows SHL Medical to increase its automation capacity in Europe further and leverage synergies…

More Than Cancer and QuestPrehab™ Team Up to Provide Digital Prehabilitation…

The partnership between More-Than-Cancer and QuestPrehab™ signifies a shared commitment to support patients by integrating prehabilitation, a proactive health management strategy aimed at enhancing patient resilience ahead of significant surgeries and cancer treatments. Prehabilitation is proven to improve clinical outcomes and shorten recovery time. The collaboration provides More-Than-Cancer a distinctive edge by diversifying its service offerings, while QuestPrehab™ can positively impact more…

Casino Group Communication

Update on the requests from the conciliators ( conciliateurs )Paris, 3 July 2023As announced on 21 June, the conciliators ( conciliateurs ) have asked for the benefit of the Group, for the duration of the conciliation proceedings (i.e. until the 25th of October at the latest, to a standstill for any payment of interests and other fees (i.e. circa €130 million), and instalments of principal (i.e. circa €70 million) owed over this period by the Group companies benefiting from conciliation...

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – July 3 , 2023 – 8 .00AM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a transparency notification on June 30, 2023, from...

Altri Comunicati